US Patent 8,334,373: Claim Scope, Expiration, Litigation Risk, and siRNA Patent Landscape

US Patent 8,334,373 covers chemically modified double-stranded RNA molecules, pharmaceutical compositions containing them, and methods of formulating them. Its core limitation is sequence-pattern-directed 2′ modification of the antisense strand: every uridine in a 5′-UA-3′ motif and every cytidine in a 5′-CA-3′ motif must be 2′ modified. The patent is a platform patent rather than a target-specific drug patent. It can therefore reach multiple siRNA products if their duplexes satisfy the required sequence and chemical-modification limitations.

The main commercial issue is claim overlap with later siRNA chemistry patents, product-specific formulation patents, delivery patents, and target-specific method-of-use patents. A product can avoid US 8,334,373 while remaining blocked by other patent families.

What does US Patent 8,334,373 protect?

The patent protects a chemically modified dsRNA duplex with four central attributes:

A sense strand and an antisense strand.
Increased stability in a biological sample.
Modification of both strands.
Mandatory modification of specific antisense-strand sequence motifs:
- Every 5′-UA-3′ occurrence must contain a 2′-modified uridine.
- Every 5′-CA-3′ occurrence must contain a 2′-modified cytidine.

Claims 1 through 9 cover the dsRNA molecule and progressively add motif-count and sense-strand limitations. Claims 10 and 11 cover formulation and pharmaceutical composition. Claims 12 through 22 repeat the same architecture with an express requirement that both strands be 2′ modified.

The patent does not require a particular:

Target gene;
siRNA sequence;
guide-strand length;
passenger-strand length;
overhang structure;
conjugate;
lipid nanoparticle;
route of administration;
disease indication; or
mammalian species beyond the composition claim's mammal limitation.

That absence makes the independent molecule claims potentially broad across target classes, subject to the required motif and modification pattern.

How do the independent claims differ?

Claim	Category	Principal scope
1	dsRNA molecule	Both strands modified; antisense UA and CA motif modifications required
10	Preparation method	Formulating the dsRNA of claim 1 in a pharmaceutically acceptable carrier
11	Pharmaceutical composition	dsRNA of claim 1 plus carrier for inhibiting target-gene expression in a mammal
12	dsRNA molecule	Same core structure, but both strands are expressly 2′ modified
21	Preparation method	Formulating the dsRNA of claim 12
22	Pharmaceutical composition	dsRNA of claim 12 plus carrier

Claim 12 is narrower in wording than claim 1 because it expressly requires 2′ modification on both strands. Claim 1 states that both strands are “modified,” but does not expressly confine every sense-strand modification to the 2′ position.

The two independent molecule claims do not require that every nucleotide in either strand be modified. They require motif-specific modifications on the antisense strand, with additional sense-strand limitations appearing in dependent claims.

What sequence motifs trigger infringement risk?

The critical antisense motifs are:

Motif	Required modification
5′-UA-3′	The uridine must be 2′ modified
5′-CA-3′	The cytidine must be 2′ modified

The phrase “in all occurrences” is central. A duplex with four antisense UA motifs and three antisense CA motifs would need the relevant seven nucleotides to be modified to satisfy the core limitation. Modification of only selected occurrences would create a substantial non-infringement position for the literal claim, although doctrine-of-equivalents issues could remain fact dependent.

Claims 3 and 4 narrow the molecule by requiring at least two or at least three occurrences of one or more covered motifs. Those claims do not expand the core patent scope. They create fallback positions if a court construes the independent claims broadly but finds a minimum motif-count limitation relevant to validity or infringement.

What chemical modifications are covered?

Claim 6 and claim 17 list the following 2′ modifications:

2′-deoxy;
2′-O-methyl;
2′-deoxyfluoro;
2′-O-methoxyethyl, or 2′-O-MOE;
2′-O-N-methylacetamido, or 2′-O-NMA;
2′-O-dimethylaminoethoxyethyl, or 2′-O-DMAEOE;
2′-O-aminopropyl, or 2′-O-AP;
2′-ara-F; and
locked nucleic acid, or LNA, nucleotides.

The list is important but should not automatically be treated as an exhaustive definition of every potentially covered 2′ modification. The independent claims refer more generally to “2′-modified” nucleotides, while the dependent claims identify specific examples. A non-listed 2′ modification could still fall within an independent claim if it satisfies the claim construction adopted by a court.

The patent also distinguishes between general 2′ modification and 2′-O modification. Claim 5 permits certain unmodified sense-strand dinucleotides:

5′-UU-3′;
5′-UG-3′;
5′-UC-3′;
5′-CU-3′;
5′-CG-3′; and
5′-CC-3′.

Neither nucleotide in the specified dinucleotide may be 2′-O modified. This limitation gives claim 5 a defined pattern of permitted unmodified regions and may be useful as a validity fallback.

What additional sense-strand modifications are claimed?

Claims 7 through 9 add sense-strand motif modifications:

Sense-strand motif	Required modification
5′-UG-3′	2′-modified uridine
5′-UU-3′	2′ modification of the 5′-most uridine
5′-CC-3′	2′ modification of the 5′-most cytidine
5′-CU-3′	2′-modified cytidine
5′-UC-3′	2′-modified uridine

Claim 8 requires at least one of the UG or UU features. Claim 9 requires both. These provisions narrow the patent toward duplexes with coordinated stabilization patterns on both strands.

Claims 18 through 20 appear intended to repeat this sense-strand subject matter for the claim 12 branch. Claims 19 and 20, however, refer to “claim 7” rather than claim 18. As issued, that creates a formal dependency issue. Claims 19 and 20 therefore appear to depend on claim 7 as written, not claim 18. The error may affect claim interpretation, correction, and prosecution-history analysis.

How broad is the patent against commercial siRNA products?

The patent is potentially relevant where a commercial siRNA has:

an antisense UA or CA motif;
2′ modification at every applicable motif position;
modification on both strands;
a duplex architecture within the claim's dsRNA scope; and
a pharmaceutical or biological use consistent with the asserted claim.

It is less likely to read literally on a duplex where:

the antisense strand contains no UA or CA motifs;
at least one UA or CA occurrence is intentionally unmodified;
the relevant nucleotide is modified at a position other than 2′;
the molecule is single stranded rather than double stranded;
the product uses a chemical architecture outside the claim construction for “2′ modified”; or
the accused product's actual sequence differs from the sequence represented in regulatory and manufacturing records.

Sequence analysis must be performed on the actual antisense strand in the 5′ to 3′ orientation. A complementary sequence can create or eliminate UA and CA motifs depending on strand orientation.

When does US 8,334,373 lose exclusivity?

The ordinary US patent term is 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any statutory adjustment. The relevant priority chain and USPTO term data should control the operative expiration date. The patent issued on December 18, 2012, but the issue date does not determine expiration. [1][2]

For commercial planning, the patent should be treated as a late-life platform patent if its earliest nonprovisional priority falls in the mid-2000s. Any remaining enforceability must be checked against:

USPTO maintenance-fee records;
patent-term-adjustment calculation;
terminal disclaimers;
reexamination or post-grant proceedings;
disclaimers or certificates of correction; and
court judgments affecting particular claims.

A patent can remain listed in public databases after enforceability has changed. A current USPTO Patent Center record is controlling for prosecution and maintenance events. [2]

What is the Orange Book status of US 8,334,373?

US 8,334,373 is a platform dsRNA patent, not a patent directed to a named FDA-approved drug, active ingredient, dosage form, or approved indication. It would not ordinarily be listed in the Orange Book merely because it covers a class of modified siRNA molecules.

Orange Book listing generally depends on the patent's relationship to an approved drug product and the statutory categories for listed patents, including drug substance, drug product, and method-of-use patents. FDA regulations require the NDA holder to submit patent information that meets those requirements. [3][4]

The practical consequences are:

The patent does not automatically create an ANDA Paragraph IV pathway.
A generic applicant would need to address patents actually listed against the relevant reference-listed drug.
The patent can still be asserted under ordinary patent law against a product, even if it is not Orange Book listed.
A patent directed to a formulation, conjugate, delivery system, or method of treatment may be more commercially important than this platform patent for an approved siRNA product.

What Paragraph IV challenges could arise?

A Paragraph IV certification would be relevant only if US 8,334,373 were listed for the applicable reference product. The likely attack positions would include:

Non-infringement because the accused antisense sequence lacks a UA or CA motif.
Non-infringement because one or more motif nucleotides are not 2′ modified.
Invalidity for anticipation based on earlier modified-siRNA disclosures.
Obviousness based on prior disclosures of 2′-O-methyl, 2′-fluoro, LNA, or related modifications.
Indefiniteness or claim-construction disputes over “increased stability in a biological sample.”
Written-description or enablement challenges directed to the breadth of sequence-independent coverage.
Formal dependency objections involving claims 19 and 20.

The “increased stability” language may create an evidentiary issue. A challenger could argue that stability must be demonstrated against a defined comparator and biological sample. The patentee would likely rely on the specification, examples, and prosecution history to establish the comparison standard.

What patent landscape surrounds this patent?

US 8,334,373 sits within several overlapping siRNA patent layers.

Patent layer	Typical protected subject matter	Relevance to this patent
Core siRNA chemistry	2′-O-methyl, 2′-fluoro, LNA, phosphorothioate and related modifications	Directly overlapping technical field
Motif-directed stabilization	Modification of selected dinucleotide contexts	Closest conceptual overlap
Conjugated siRNA	GalNAc, cholesterol, ligand, peptide or other conjugates	May block commercial delivery even if the duplex avoids this patent
Lipid nanoparticle delivery	Lipid composition, particle structure and manufacturing	Independent product risk
Target-specific sequence patents	Particular guide sequences and target genes	Can create blocking rights for individual drugs
Formulation patents	Buffer, salt, concentration, excipients and storage conditions	Relevant to injectable products
Manufacturing patents	Solid-phase synthesis, purification, annealing and scale-up	May create process risk
Method-of-use patents	Treatment of disease or patient subgroup	Relevant after approval
Regulatory patents	Drug-device combinations and administration systems	Relevant to marketed presentations

The main competitive owners in the broader siRNA field have included Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Silence Therapeutics, Novartis, Merck and Roche-affiliated entities. Ownership varies by patent family, acquisition, assignment and license. A portfolio review must therefore separate original inventorship from current assignee and commercial licensee.

How does this patent compare with product-specific patents?

US 8,334,373 is broad in target coverage but narrow in chemical pattern. Product-specific patents are usually narrower in sequence but stronger commercially because they can attach directly to an approved drug.

Issue	US 8,334,373	Product-specific patent
Target gene	Not required	Usually specified
Sequence	Not specified	Usually exact or highly constrained
Chemistry	Motif-directed 2′ modification	May cover exact pattern or conjugate
Delivery	Not required	Often covered separately
Formulation	Broad carrier language	Usually specific composition
FDA listing	Not ordinarily drug-linked	More likely if tied to an approved NDA
Design-around potential	Sequence and modification changes may help	More difficult if exact drug sequence is claimed
Litigation value	Platform-wide	High for the marketed product

What generic launch risks exist?

A generic or follow-on siRNA launch would face several independent barriers:

The product sequence may fall within the UA/CA motif claims.
A different modification pattern may avoid this patent but reduce stability or activity.
A changed sequence may affect potency, off-target profile, or regulatory comparability.
Delivery technology may be separately patented.
The reference product's formulation may be protected.
Manufacturing and purification processes may be unavailable or separately licensed.
The regulatory pathway may not fit a conventional small-molecule ANDA model.

Biosimilar risk is generally limited. siRNA products are nucleic-acid medicines, not conventional therapeutic proteins. A follow-on product may proceed through an ANDA, 505(b)(2), or another pathway depending on product characteristics and FDA classification. Biosimilar provisions under section 351(k) are principally relevant to biological products and do not automatically apply to every nucleic-acid therapeutic. [5]

What litigation and settlement issues matter?

No litigation conclusion should be drawn from the patent number alone. The relevant review must distinguish:

cases naming US 8,334,373 specifically;
cases involving continuation or divisional patents in the same family;
disputes over related siRNA chemistry patents;
settlements that grant a license without admitting validity;
covenants not to sue;
geographic restrictions;
field-of-use restrictions; and
royalty-bearing licenses.

A settlement involving a related Alnylam or siRNA platform patent does not necessarily authorize practice of US 8,334,373. Conversely, a license to a broader platform portfolio may include this patent even if it is not named in public commercial materials.

What is the overall patent strength?

The patent has meaningful platform breadth but several litigation vulnerabilities.

Strength	Assessment
Target coverage	Strong; no target-specific limitation
Sequence coverage	Broad in theory, limited by UA/CA motif occurrence
Chemical coverage	Broad if “2′ modified” is construed expansively
Claim clarity	Moderate; “increased stability” and modification wording may require construction
Design-around potential	Moderate; sequence and motif changes can avoid literal scope
Product relevance	High for qualifying duplexes, low for products lacking the motifs
Orange Book leverage	Generally limited absent product-specific listing
Validity risk	Moderate, given the breadth of the platform claims and prior-art field
Commercial blocking value	Depends heavily on sequence analysis and related patent families

Key Takeaways

US 8,334,373 is a platform patent for motif-directed chemical stabilization of dsRNA.
The core antisense requirements are 2′ modification of every uridine in 5′-UA-3′ motifs and every cytidine in 5′-CA-3′ motifs.
Claims 12 through 22 expressly require 2′ modification of both strands.
The patent does not require a specific target, sequence, disease, conjugate, or delivery system.
Claims 19 and 20 contain an apparent dependency error because they refer to claim 7 rather than claim 18.
The patent is not inherently an Orange Book patent and does not automatically create Paragraph IV exposure.
Commercial risk depends on the actual antisense sequence, exact modification map, formulation, delivery platform, manufacturing process, and related patent families.
A product can avoid US 8,334,373 yet remain blocked by formulation, conjugate, delivery, sequence, method-of-use, or manufacturing patents.

FAQs

Does US 8,334,373 cover all chemically modified siRNA molecules?

No. It requires specific antisense UA and CA motif modifications and requires modification of both strands. siRNAs without the relevant motifs, or with an unmodified covered motif, may avoid literal infringement.

Does a 2′-O-methyl modification automatically infringe this patent?

No. The modification must occur at the required nucleotide positions in the relevant UA or CA motifs, and the duplex must satisfy the remaining claim limitations.

Is US 8,334,373 relevant to GalNAc-siRNA products?

Potentially. GalNAc attachment does not by itself avoid the patent. The underlying duplex sequence and modification map must be compared with the claims. GalNAc conjugation may also be covered by separate patent families.

Can an siRNA company design around this patent by changing the guide sequence?

Potentially. Eliminating antisense UA and CA motifs, or leaving at least one required motif nucleotide unmodified, may avoid literal scope. The redesigned sequence must then be reviewed against target-specific, conjugate, delivery and formulation patents.

Does patent expiration eliminate all US exclusivity for an siRNA drug?

No. Expiration of one platform patent does not eliminate unexpired patents covering the drug's sequence, conjugate, delivery system, formulation, method of use, manufacturing process or device.

References

United States Patent No. 8,334,373. (2012). Modified double-stranded RNA molecules and compositions containing same. United States Patent and Trademark Office.
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
Code of Federal Regulations. (2024). 21 C.F.R. § 314.53, Submission of patent information.
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005247509	⤷ Start Trial
Canada	2568013	⤷ Start Trial
European Patent Office	1765847	⤷ Start Trial
European Patent Office	2399924	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2005115481	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,334,373

Summary for Patent: 8,334,373